Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Assay Type | Inhibition-TR-FRET |
Analyte | Human IgG, Human IgG Fc protein, Human FcRn inhibitors, Anti-human FcRn antibody |
Format | 100T/500T |
Reactivity | Human |
Regulatory Status | RUO |
Sensitivity | IC50=20.14 μg/mL |
Standard Curve Range | 0.24 μg/mL-1000 μg/mL |
Assay Time | 1 hr |
Suitable Sample Type | For the binding of IgG Fc region to the human FcRn receptor |
Sample volume | 10 μL |
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
ID | Components | Size |
FRT01-C01 | Human FCRN&B2M Heterodimer Protein Europium-chelate | 100 tests/500 tests |
FRT01-C02 | FA labeled human IgG antibody | 100 tests/500 tests |
FRT01-C03 | Human IgG standard | 200 μg/100 tests 1 mg/500 tests |
FRT01-C04 | Sample Dilution Buffer | 10 mL/100 tests & 500 tests |
FRT01-C05 | Detection Buffer | 10 mL/100 tests & 500 tests |
Inhibition Assay of interaction of Human FcRn and Human IgG1 antibody by Human IgG standard in a homogeneous (no wash) TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) competition assay, with a typical IC50 of 20.14 μg/mL (QC tested).
The kit has been used to detect different subclasses of Human IgG Fc proteins, which exhibit different IC50 results as expected.
The kit has been used to detect different subclasses of Human IgG, which exhibit different IC50 results as expected.
The kit has been used to detect the binding activity between Human FcRn and Human IgG standard under different pH. The IC50 shows a significant increase with increasing pH, which corelates with a decreased binding between Human FcRn and Human IgG standard.
The half-lives of these 3 monoclonal antibodies currently in clinical use generally correlate with the binding affinity to FcRn. The kit has been used to detect 3 FDA approved antibody drugs of different binding affinity to FcRn, and the IC50 trends are consistent with affinity constant from SPR as well as the actual in vivo half-life published.
The kit is suitable for the detection of FcRn inhibitors. It shows that both Efgartigimod and its biosimilar, Human IgG1 Fc (C103S, M135Y, S137T, T139E, H316K, N317F) His Tag (Cat. No. IG1-H52H8) exhibit good inhibitory activity in this TR-FRET competition assay.
Price(USD) : $770.00
Price(USD) : $2575.00
Price(USD) : Inquire
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Efgartigimod alfa | ARGX-113; EFG PH20; EFG PH20 SC; PH20 SC; ARGX-113-2308 | Approved | Argenx Se | VYVGART HYTRULO, VYVDURA, VYVGART, 卫伟迦 | United States | Myasthenia Gravis | Argenx BV | 2021-12-17 | Graves Ophthalmopathy; Tachycardia; Pemphigus; Thrombocytopenia; Guillain-Barre Syndrome; Eye Diseases; Nephrotic Syndrome; Muscular Diseases; Pemphigoid, Bullous; Optic Neuritis; Glomerulonephritis, Membranous; Rejection of organ transplantation; Purpura, Thrombocytopenic, Idiopathic; Lupus Nephritis; Scleroderma, Systemic; Sjogren's Syndrome; Stiff-Person Syndrome; Postural Orthostatic Tachycardia Syndrome; Polyneuropathies; Myositis; Nephrosis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Myasthenia Gravis | Details |
Rozanolixizumab | UCB-7665 | Approved | Ucb Sa | RYSTIGGO | United States | Myasthenia Gravis | Ucb Inc | 2023-06-27 | Myasthenia Gravis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic; Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease; Encephalitis; Fibromyalgia | Details |
Efgartigimod alfa/Hyaluronidase | Approved | Argenx BV | VYVDURA, VYVGART HYTRULO | United States | Myasthenia Gravis | Argenx BV | 2023-06-20 | Polymyositis; Myasthenia Gravis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Myositis; Dermatomyositis; Autoimmune Diseases; Muscular Diseases | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
IMVT-1402 | IMVT-1402; HL-161 ANS | Phase 2 Clinical | HanAll Biopharma Co Ltd | Autoimmune Diseases; Graves Disease | Details |
STSA-1301 | STSA-1301; STSA1301 | Phase 1 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Purpura, Thrombocytopenic, Idiopathic | Details |
This web search service is supported by Google Inc.